Psoriasis Palmaris, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Plantaris, Psoriasis Nail
Conditions
Keywords
Psoriasis, tildrakizumab, difficult-to-treat areas
Brief summary
Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population.Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar localizations. Tildrakizumab, an anti-interleukin-23 (IL-23) monoclonal antibody, has demonstrated efficacy and safety in the treatment of patients with moderate to severe psoriasis. Real-life data on the efficacy of Tildrakizumab in unselected patients with these difficult-to-treat locations are still limited. The aim of the ZODIPSO study is to evaluate the efficacy and safety of Tildrakizumab in patients presented difficult to treat locations in psoriasis : nail, scalp, genital and palmoplantar. The main objective is to assess the overall response and the specific response to Tildrakizumab at these specific areas up to W52.
Detailed description
Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population. Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar localizations. They are reported at least once during the course of psoriatic disease in more than 80%, 50%, 60%, 12% of patients, respectively. Despite recent progress in the management of the disease, these localizations remain a challenge for psoriasis patients because of their impact on quality of life and the difficulty of treating them. Tildrakizumab, an anti-interleukin-23 (IL-23) monoclonal antibody, has already demonstrated efficacy and safety in the treatment of patients with moderate to severe psoriasis in two international multicenter randomized clinical trials : reSURFACE 1 and reSURFACE 2. However, real-life data on the efficacy of Tildrakizumab in unselected patients with these difficult-to-treat locations are still limited.
Interventions
OTHERPsoriasis clinical assessments
Global evaluation of psoriasis and specific evaluation by areas
DLQI questionnaire at each visit
Visual analogic scale at W16, W28, W52
OTHERPruritus evaluation
Visual analogic scale at each visit
Sponsors
Clin4all
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with a diagnosis of moderate to severe chronic plaque psoriasis documented in the medical record, 2. Disease diagnosis \> 6 months (regardless of severity at diagnosis) 3. Involvement of at least one of the following areas: nails, scalp, genital, palmoplantar (non-pustular) 4. Indication for treatment by IL-23 inhibitor. Tildrakizumab must be the selected IL-23 inhibitor therapy prior to enrolling the patient in the study. Patients who have previously received previous treatment by IL-23 inhibitors may be included. 5. Patient 18 years of age or older at the inclusion visit 6. French social security beneficiary
Exclusion criteria
1. Patient unable to comply with study requirements (i.e.complete study questionnaires) 2. Patient who, in the opinion of the investigator, should not participate in the study. This opinion should be documented in the patient's record. 3. Patient included in an interventional clinical trial at inclusion. 4. Vulnerable patient or patient under court protection 5. Patients with known hypersensitivity to IL-23 inhibitors 6. Patients with HIV or active HBV or HCV infection at the time of inclusion 7. Patient with a history of untreated latent tuberculosis or active tuberculosis at inclusion 8. Patient with any other serious active infection present at inclusion that contraindicates IL23 inhibitors use. 9. Pregnant or lactating woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Specific response to Tildrakizumab at W28 | Week 28 | Percentage of response based on specific assessment on target area (75% improvement of the specific score compared to Baseline visit) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Specific response to Tildrakizumab | Week 16, week 28 and week 52 | Percentage of response based on specific assessment by area compared to Baseline Visit |
| Adverse events | From baseline visit to Week 52 | Describe adverse events throughout follow-up |
| Overall response to Tildrakizumab | Each visit (Week16-Week 28-Week 52) | Percentage of response based on global assessment compared to Baseline visit |
| Evaluation of quality of life under treatement | Each visit (Baseline, Week16, Week 28, Week 52) | Dermatology Life Quality Index (DLQI) score compared to Baseline Visit |
| Evaluation of satisfaction under treatement | Each follow-up visit (Week 16, Week 28, Week 52) | Variation in visual analogic scale (VAS) value |
| Evaluation of pruritus under treatment | Each visit (Baseline,Week 16, Week 28, Week 52) | Variation in visual analogic scale (VAS) value |
Countries
France
Outcome results
None listed